

**STERLING BIOTECH LIMITED**

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31 MARCH 2011**

(₹ in Lacs)

Sr. No.	Particulars	Quarter ended 31/03/2011	Corresponding Quarter ended 31/03/2010	For the Year ended 31/12/2010	For the Year ended 31/12/2009
		Unaudited	Unaudited	Unaudited	Audited
1	Income				
	a) Net Sales/Income from Operations	43,828.15	38,278.25	161,657.85	143,817.29
	b) Other Operating Income	326.35	212.34	1,063.76	886.42
	<b>c) Total</b>	<b>44,154.50</b>	<b>38,490.59</b>	<b>162,721.61</b>	<b>144,703.71</b>
2	Expenditure				
	a) (Increase)/decrease in stock in trade and work in progress	(4,688.02)	(1,067.84)	(9,332.32)	(17,130.11)
	b) Consumption of raw materials	19,871.48	15,082.57	66,883.27	77,749.36
	c) Employees Cost	1,178.92	1,022.47	4,513.05	4,017.22
	d) Depreciation	5,914.54	3,223.85	19,762.17	12,304.21
	e) Other expenditure	7,648.79	7,365.63	29,885.61	28,629.32
	<b>f) Total</b>	<b>29,925.71</b>	<b>25,626.68</b>	<b>111,711.78</b>	<b>105,570.00</b>
3	Profit / (Loss) from Operations before Other Income and Interest (1-2)	14,228.79	12,863.91	51,009.83	39,133.71
4	Other Income	0.00	0.00	0.00	0.00
5	Profit / (Loss) before Interest (3+4)	14,228.79	12,863.91	51,009.83	39,133.71
6	Interest	6,317.64	5,527.54	23,047.05	14,943.77
7	<b>Profit / (Loss) from Ordinary Activities before tax (5-6)</b>	<b>7,911.15</b>	<b>7,336.37</b>	<b>27,962.78</b>	<b>24,189.94</b>
8	Tax expense				
	a) Current	1,560.00	1,210.00	4,020.00	3,500.00
	b) Deferred	1,100.00	1,200.00	3,100.00	3,350.00
	c) Fringe Benefit	0.00	0.00	0.00	12.50
	d) Total	2,660.00	2,410.00	7,120.00	6,862.50
9	<b>Net Profit / (Loss) from Ordinary Activities after tax (7-8)</b>	<b>5,251.15</b>	<b>4,926.37</b>	<b>20,842.78</b>	<b>17,327.44</b>
10	Extraordinary Items	(121.87)	(222.18)	(6,310.48)	6,205.12
11	<b>Net Profit / (Loss) for the period (9-10)</b>	<b>5,129.28</b>	<b>4,704.19</b>	<b>14,532.30</b>	<b>23,532.56</b>
12	Prior year adjustment	0.00	0.00	0.00	166.97
13	<b>Profit available for appropriation</b>	<b>5,129.28</b>	<b>4,704.19</b>	<b>14,532.30</b>	<b>23,699.53</b>
14	Paid-up equity share capital (Face Value of Re.1/- per share)	2,678.74	2,501.97	2,678.74	2,501.97
15	Reserves excluding Revaluation Reserves as per balance sheet.				204,530.55
16	Earnings Per Share (EPS)				
	a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.				
	Basic	1.96	1.97	8.16	6.98
	Diluted	1.74	1.63	7.19	5.72
	b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized) on F.V. of Re.1/- per share.				
	Basic	1.91	1.88	5.69	9.47
	Diluted	1.70	1.56	5.01	7.77
17	Public Shareholding				
	- Number of shares	133,666,531	133,666,531	133,666,531	133,666,531
	- Percentage of shareholding	49.90%	53.42%	49.90%	53.42%

## STERLING BIOTECH LIMITED

Regd. Office: 43, Atlanta Building, Nariman Point, Mumbai - 400 021

### UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE FIRST QUARTER ENDED 31 MARCH 2011

(₹ in Lacs)

Sr. No.	Particulars	Quarter ended 31/03/2011	Corresponding Quarter ended 31/03/2010	For the Year ended 31/12/2010	For the Year ended 31/12/2009
		Unaudited	Unaudited	Unaudited	Audited
18	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	Number of shares	21,428,340	30,527,000	18,228,340	30,527,000
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	24.07%	34.29%	20.47%	34.29%
	Percentage of shares (as a % of the total share capital of the Company)	8.00%	12.20%	6.80%	12.20%
	b) Non-encumbered				
	Number of shares	67,606,354	58,507,694	70,806,354	58,507,694
	Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	75.93%	65.71%	79.53%	65.71%
	Percentage of shares (as a % of the total share capital of the Company)	25.24%	23.38%	26.43%	23.38%

**Notes:**

- 1 The company's operations fall under single segment hence segment reporting as defined in Accounting Standard 17 is not applicable.
- 2 The above Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors in its meeting held on 14 May 2011.
- 3 The Statutory Auditors have carried out a limited review of the financial results for the quarter ended 31 March 2011.
- 4 The number of investor complaints for the quarter ended on 31 March 2011 were :  
Opening - NIL, Received - 19, Disposed off - 19, and Balance - NIL.
- 5 Previous period figures have been regrouped/reclassified, wherever necessary.

For and on Behalf of  
**STERLING BIOTECH LIMITED**

Place : Mumbai  
Date : 14 May 2011.

**Chetan J. Sandesara**  
Joint Managing Director